Partnering for Shared Success! Topfond Pharmaceutical Invites You to Visit Us at CPHI & PMEC China 2026.
CPHI & PMEC China 2026
跨越千里,相聚沪上。为进一步开拓全球医药市场、深化产业协作,天方药业将出席第二十四届世界制药原料中国展暨第十九届世界制药机械、包装设备与材料中国展(CPHI & PMEC China 2026)。天方药业秉持专业、务实的态度,期待与全球同仁一道,发掘医药领域新契机。我们诚挚邀请海内外新老客户及合作伙伴莅临展位,现场交流,共促业务发展。
Bridging distances, we meet in Shanghai. To further expand the global pharmaceutical market and deepen industry collaboration, Topfond Pharmaceutical Co., Ltd. will attend the 24th CPHI China & 19th PMEC China. With a professional and pragmatic approach, Topfond looks forward to exploring new opportunities in the pharmaceutical field together with partners and professionals from around the world. We sincerely invite valued customers, prospective client, and business partners worldwide to visit our booth for face-to-face exchanges and joint business growth.
行业盛会,共绘蓝图
Industry gathering, shaping the future together.
CPHI & PMEC China 2026 是亚洲规模最大的制药产业展会之一,以240,000平方米展示面积汇聚3,600家展商,预计吸引来自150余个国家和地区的逾110,000人次专业人士共聚盛会。展会内容涵盖制药原辅料、CRO&CMO、生物制药、包装及给药系统、实验室仪器等制药工业垂直领域,是全球制药企业拓展海外市场、对接优质资源的重要商贸交流平台。
CPHI&PMEC China 2026 is one of the largest pharmaceutical industry exhibitions in Asia. Covering 240,000 square meters, the event will bring together 3,600 exhibitors and is expected to attract over 110,000 professionals from more than 150 countries and regions. The exhibition spans a wide range of pharmaceutical industry sectors, including pharmaceutical ingredients and excipients,CRO/CMO services, biopharmaceuticals, packaging and drug delivery systems, as well as laboratory instruments. It serves as a vital business and trade platform for global pharmaceutical companies to expand overseas markets and connect with quality resources.
央企品质,保供稳链
State-owned strength, reliable supply assurance
天方药业有限公司(简称“天方药业”)成立于1969年,2000年在上海证券交易所上市,是一家集科、工、贸于一体的大型综合性医药企业。公司拥有五大子公司、两个生产基地(占地超80万平方米,建筑面积40万平方米),员工3000余人,总资产近70亿元。
天方药业坚持以成品制剂、化学合成原料药和生物发酵原料药为核心业务,构建了“中间体—原料药—制剂”一体化产业链。公司在林可胺类、大环内酯类、他汀类等领域拥有国际领先的生产能力,其中盐酸林可霉素年产能1300吨,获得CEP认证;克林霉素磷酸酯、辛伐他汀(获CEP/US-FDA/ANVISA)、曲克芦丁(CEP)等原料药远销全球。同时,公司拥有片剂、注射剂、胶囊剂、软膏剂等多种剂型生产线,年产片剂8亿片、注射剂8千万支、胶囊剂8亿粒,核心制剂包括阿托伐他汀钙片、非那雄胺片、他达拉非片、硫辛酸注射液等。
本次参展,天方药业将聚焦原料药优质供应、制剂技术升级、海内外渠道合作等方向,积极对接全球客商,依托过硬产能与品质优势,持续拓展国际医药合作版图。此外,还将同步展出天山制药(国内首家以现代技术量产甘草及甘草衍生制品的药企,主导起草甘草制品国家标准)的甘草原料药系列产品,包括甘草酸单铵盐、甘草次酸、甘草酸二钾等。
天方药业先后荣获“国家高新技术企业”、“国家绿色工厂”、“河南省医药生产龙头企业”、“河南省重点出口企业”等称号,商标被认定为“中国驰名商标”。公司严格遵循GMP、CEP、USP、EP等国际标准,建立了全流程质量追溯体系,产品远销欧洲、美洲、东南亚、中东等几十个国家和地区。
Topfond Pharmaceutical Co., Ltd. (abbreviated as "Topfond Pharmaceutical"), established in 1969 and listed on the Shanghai Stock Exchange in 2000, is a large-scale comprehensive pharmaceutical enterprise integrating R&D, manufacturing, and commercial operations. The company operates five subsidiaries and two production bases (covering over 800,000 square meters with a total floor area of 400,000 square meters), employs more than 3,000 staff members, and has total assets of nearly 7 billion yuan.
Topfond Pharmaceutical focuses on finished pharmaceutical preparations, chemically synthesized active pharmaceutical ingredients (APIs), and biologically fermented APIs as its core business, establishing an integrated industrial chain spanning intermediates, APIs, and finished formulations. The company possesses internationally leading production capabilities in the fields of lincosamides, macrolides, and statins, with an annual production capacity of 1,300 tons of CEP-certified lincomycin hydrochloride. APIs such as clindamycin phosphate, simvastatin (certified by CEP/US FDA/ANVISA), and troxerutin (CEP-certified) are exported globally. Additionally, the company operates production lines for various dosage forms—including tablets, injections, capsules, and ointments—with annual outputs of 800 million tablets, 80 million units of injectable products, and 800 million capsules. Key products include atorvastatin calcium tablets, finasteride tablets, tadalafil tablets, and thioctic acid injection.
At this exhibition, Topfond Pharmaceutical will focus on key areas including high-quality supply of APIs, advancement in formulation technologies, and international market cooperation, actively engaging with global partners. Leveraging its robust production capacity and quality advantages, the company aims to continuously expand its globle partnership network. Additionally, it will showcase a range of licorice APIs products from Tianshan Pharmaceutical—the first domestic pharmaceutical company to mass-produce licorice and licorice-derived products using modern technology and the lead drafter of the national standard for licorice products—including monoammonium glycyrrhizinate, glycyrrhizic acid, and dipotassium glycyrrhizinate.
Topfond Pharmaceutical has successively been awarded titles such as "National High-Tech Enterprise," "National Green Factory," "Leading Pharmaceutical Manufacturing Enterprise in Henan Province," and "Key Export Enterprise of Henan Province," with its trademark recognized as a "China Well-Known Trademark." The company strictly adheres to international standards including GMP, CEP, USP, and EP, and has established a comprehensive quality traceability system. Its products are exported to dozens of countries and regions across Europe, the Americas, Southeast Asia, and the Middle East.
深耕国际,拓展版图
Strengthening globel presence, expanding new horizons
国际化是天方药业的关键发展路径。公司不断优化全球业务支撑体系,稳步推动海外市场布局落地。凭借盐酸林可霉素、克林霉素磷酸酯、辛伐他汀等多个品种的CEP证书及国际认证,天方药业已成为全球多家知名药企的稳定供应商。公司秉持开放共赢理念,积极与全球药企、科研机构开展技术交流与联合研发,同时开放供应链、渠道、项目等多元合作模式,致力于构建稳定共赢的全球化医药产业生态。
Globalization is a key development strategy for Topfond Pharmaceutical. The company continues to optimize its global business network and steadily advances the expansion of its presence in overseas markets. Leveraging CEP certificates and international certifications for multiple products—including lincomycin hydrochloride, clindamycin phosphate, and simvastatin—Topfond Pharmaceutical has become a reliable supplier to numerous renowned pharmaceutical companies worldwide. Adhering to the principle of open collaboration and mutual benefit, the company actively engages in technical exchanges and joint research initiatives with global pharmaceutical firms and research institutions, while providing opportunities for collaboration across supply chains, distribution channels, and projects, committed to building a stable and mutually beneficial global pharmaceutical industry ecosystem.
诚邀相聚,同谱新章
Join us, shaping a new future together.
本次展会,天方药业将带来重点原料药、制剂及甘草系列产品,集中展示全产业链整体能力。现场设立专属洽谈区,为您匹配个性化合作方案。欢迎全球客户及行业伙伴光临展位对接沟通,携手发掘全球机遇,共筑医药产业新格局!
At this exhibition, Topfond Pharmaceutical will showcase key APIs, formulations, and licorice product series, demonstrating comprehensive capabilities across the entire industrial chain. A dedicated meeting area will be available for in-depth business discussions and tailored partnership solutions. We warmly welcome global clients and industry partners to visit our booth for communication, jointly explore global opportunities, and co-create a new landscape for the pharmaceutical industry!
展会信息
Exhibition Information
展会名称: 第二十四届世界制药原料中国展暨第十九届世界制药机械、包装设备与材料中国展(CPHI & PMEC China 2026)
Event: The 24th CPHI China & 19th PMEC China
展会地点: 上海新国际博览中心
Venue: Shanghai New International Expo Centre (SNIEC)
展会时间: 2026年6月16日—6月18日
Dates: June 16 - June 18, 2026
天方药业展位号: W1D22a
Topfond Pharmaceutical Booth No.: W1D22a
天方药业有限公司 | Topfond Pharmaceutical Co., Ltd.
真诚期待与您在上海相聚!
We sincerely look forward to meeting you in Shanghai!
股票
板块
用户
资讯
评论 (0)